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Background and Objective. Drug dependence is one of the serious problems around the world. Sa0ron is one of those bene1cial
medicinal plants which is embedded with a similar mechanism to methadone (e.g., inhibition of serotonin reuptake). +us, it can
be helpful in reducing the withdrawal symptoms. +e aim of this study was to reduce the daily dose of methadone usage and
reduce its side e0ects using sa0ron in the form of medicinal supplements. Methodology. +is study was categorized as a clinical
trial. Accordingly, 44 clients of addiction treatment centers in Sabzevar parish were randomly selected to participate in this study
in 2016–2017. While the experimental group was treated with methadone syrup and self-made sa0ron capsules, the control group
received methadone syrup and placebo capsules. Results. +e results showed that the use of sa0ron and methadone alleviated the
symptoms of withdrawal syndrome (p< 0.001). Conclusion. Having reviewed the research participants, it was indicated that the
introduction of sa0ron alleviated the symptoms of withdrawal syndrome in patients undergoing maintenance treatment for
opioid addiction.+us, it seems rational to make use of sa0ron in combination with methadone in order to alleviate the symptoms
of withdrawal syndrome.
1. Introduction
Nowadays, the main mechanisms and brain-driven factors
that are associated with opioid dependence are known to
a large extent. It seems that the dopamine mesocorticolimbic
pathway is one of the most important pathways associated
with drug dependence that play an important and vital role
in psychological dependence to opioids [1]. +is pathway
starts from the ventral tegmental area, which is considered
the A10 dopamine neurons, and ends in nucleus accumbens,
frontal cortex, and other areas involved in memory, such as
the hippocampus and amygdala. However, other anatomical
pathways and neurotransmitters have been identi1ed in the
brain which may be at least attributed to a portion of the
opioid-induced psychological dependence. Since opioid
drugs stimulate dopamine release in the mesocorticolimbic
pathways, it is argued that these drugs can also induce long-
term memory [3].
+e withdrawal syndrome is a syndrome which occurs
when blood or tissue concentrations of a substance drop in an
individual who has used large amounts of the substance for
a long time. Although the symptoms of each substance are
unique, there are some similar symptoms (e.g., substance
carving) [4]. +e importance of withdrawal syndrome may be
inferred through more probable relapse; the patient’s distress;
immediate health risks (cardiovascular instability); mental
disorders associated with withdrawal (such as depression
induced by opioids) [5]; physical symptoms including tremor,
muscle cramps, bone andmuscle pain, chill, sweating, rhinitis,
@u-like symptoms, diarrhea, yawning, sneezing, tachycardia,
Hindawi
Advances in Medicine
Volume 2017, Article ID 1079132, 5 pages
https://doi.org/10.1155/2017/1079132
etc.; psychological symptoms, including dysphoria, de-
pression, anxiety, or panic attacks; dizziness; agitation; as well
as rare but serious symptoms, including cardiac arrhythmia,
stroke, seizure, and suicide [6, 7].
+e latter can be diagnosed through interview and
clinical examination. However, the urine test may be used to
con1rm the diagnosis [8].
+e onset of withdrawal symptoms for short-acting
opioids, such as morphine and heroin, lasts from 1 to 7
days, which starts within 8 to 12 hours after the last con-
sumption and reaches the maximum level up to 48 hours.
Given the long-acting opioids, such as methadone, it is
observed that the onset of withdrawal symptoms lasts from 7
to 10 days and reaches the maximum level up to 3 to 8 days,
and these symptoms continue up to few weeks. It should be
noted that its nonspeci1c binding to tissues generates a great
source of methadone in the body. +is source prevents from
rapid drug drop-o0 and, thus, it is rational to prescribe it
once a day [9, 10].
+e treatment of withdrawal or deprivation syndrome
consists of providing supportive therapy, including treat-
ment of @uid and electrolyte disorders, and paying due
attention to the associated disorders, such as anxiety or
depression. However, the main treatment is based on such
long-acting opioids as methadone. If the patient feels pain,
nonsteroidal anti-in@ammatory drugs (NSAIDs) are pre-
ferred, but if there is a medical prohibition (e.g., stomach
ulcer), one can increase the methadone dose. Besides, some
ancillary medications such as clonidine, trazodone, and
ondansetron are used for symptomatic treatment [11].
+e inhibition of serotonin reuptake is one of the
mechanisms of methadone through which the addict’s
general and mental conditions are improved. Similarly,
sa0ron is characterized with the same mechanism and,
additionally, it is embedded with anti-in@ammatory and
analgesic e0ects. Since the forenamed e0ects have been
con1rmed throughout the previous studies, it may be argued
that sa0ron is highly recommended to be used as an ancillary
medication to reduce the dose of methadone. In this paper, it
was attempted to investigate and compare the e0ect of
sa0ron and placebo on patients undergoing methadone
treatment [12, 13].
Since herbal medicines are characterized with fewer side
e0ects, they have been considered as ideal alternatives for
chemical drugs in the past few decades, and they are pre-
scribed in a rising trend [14]. Sa0ron is one of the plants that
have been used as a medicinal plant since ancient times in
di0erent parts of the world [15]. In Iran, this plant has been
used as an antispasmodic, tranquilizer, digestion facilitator,
anti@atulence, sudatory, mucous, pain-relieving, pain and
sexual-arousal medication [14].
Sa0ron is full of fatty substances, minerals, and
mucilage. Other compounds include a colorless essence
consisting of terpenes and cineol. It should be noted that
the smell of sa0ron is related to these materials. Picrocrocin
is a bitter heteroside which easily dissolves in water and
alcohol and brings up a glocoside whose hydrolysis gen-
erates glucose and picrocrocin. Crocin is a carotenoid
that constitutes the main component of sa0ron [16]. It is
supposed that the antidepressant e0ect of sa0ron stems
from crocin and safranal located in the stigma. Crocin
functions as a water-soluble compound and safranal
functions as a fat-soluble compound. Accordingly, they are
embedded with two di0erent mechanisms. It is postulated
that crocin a0ects the dopaminergic system and norepi-
nephrine reuptake inhibition, and safranal a0ects the se-
rotonergic system [14]. A new study suggests that crocin
(major alkaloid of sa0ron) boosts the level of dopamine in
the striatum and prevents the destruction of dopamine
neurons [17].
2. Materials and Methods
+is study was categorized as a clinical trial. Accordingly,
clients of addiction treatment centers in Sabzevar parish were
randomly selected to participate in this study in 2016–2017.
Given the clients of addiction treatment centers whose 1les
were available in the forenamed centers in Sabzevar parish (it
should be noted that all participants were located in the
stability phase, and they received a 1xed dose of methadone
for several months and did not represent any mental and
physical symptoms), it was attempted to randomly select the
eligible individuals using computer software. Next, partici-
pants were divided into two groups. Similarly, treatment was
randomly assigned to groups in that secretary of each center,
who was unaware of the content of cards named as A and B,
delivered the cards to the selected participants. When the
participants visited the center, the cards were checked by a
physician at each center and, subsequently, the desired treat-
ment was done based on the type of the concerned card
(holders of Card A and Card B received a self-made sa0ron
capsule and a placebo capsule, resp.). Before the start of drug
intervention, a speci1c checklist was 1lled for each patient.+e
forenamed checklists contained some items on the absence of
any withdrawal symptoms (lack of any signs of physical and
psychological withdrawal symptoms and independence to
increased dose of methadone was considered the research
inclusion criterion).While the experimental group was treated
with methadone syrup and self-made sa0ron capsules (each
sa0ron capsule contained 30mg of sa0ron powder), the
control group received methadone syrup and placebo capsules
(which were similar to sa0ron capsules in terms of color and
size). +e sa0ron and placebo capsules were prescribed by the
researcher once a week for 8 weeks in the clinic (exactly at the
delivery time of weekly dose of methadone), and the patients
were forced to consume them at the same location.
Given the decrease in methadone dose during the study
period (5mg per week) and its replacement with self-made
sa0ron capsules (30mg of sa0ron powder or placebo capsule
per week), it was decided to provide telephone lines for the
patients around the clock. Besides, they were instructed that,
in case of advent of any (physical or mental) withdrawal
symptoms, they could call their corresponding physician so
that they would stop taking the capsules and receive increased
dose of methadone. Furthermore, the checklists were weekly
and in-personally 1lled in line with patients’ symptoms, and
in case of advent of withdrawal symptoms, the patients were
checked in terms of compliance with the treatment regimen
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and recommendations. If it was diagnosed that the patients
did not have the ability to continue the process of inter-
vention, they would be excluded from the research. Other-
wise, the patients would be checked again, and they would be
located in their original group. Some distinct individuals, who
were unaware of the type of treatment, undertook to control
the patients’ symptoms, collect the required data, and evaluate
the results. Finally, the results were analyzed using SPSS
Software (Version 20). It should be noted that none of the
patients met the exclusion criteria.
3. Results
Regarding the two participating groups in this study, it was
indicated that the mean age of participants was 39.55 years.
Besides, the minimum age and maximum age were desig-
nated as 21 and 67 years, respectively.
e mean age of participants in the experimental and
control groups was designated as 41.5 and 37.5 years,
respectively.
Regarding the occupation of the participants, it was
declared that 72.7% of participants in the experimental
group were self-employed. However, 63.6% of participants
in the control group were self-employed (Table 1).
e results showed that the status of subjects in con-
nection to withdrawal symptoms might be depicted in terms
of Figures 1 and 2.
Given the experimental group, it was observed that
the status of “loss of appetite” moved from 50% at the
Table 1
Measurement
unit (%)
Group 1
(experimental)
Group 2
(control)
Total number
of participants
Jobholder 9.1 9.1 9
Self-employed 72.7 63.6 68
Unemployed 18.2 27.3 22.7
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end of the 1rst month to 31.8% at the end of the second
month. Besides, it was found that loss of appetite was on
a downward trend at the beginning of the fourth week.
Regarding the control group, it was indicated that there was
no change in the sign of loss of appetite, and it was almost
constant (Figure 2).
Given the status of rhinorrhea in Group 1 (experi-
mental), there was observed a lagging downward trend. +is
downward trend moved from 40% at baseline to 27% at the
end of the secondmonth, and the forenamed trend peaked at
the beginning of the second month (18%). Regarding Group
2 (control), it was observed that the rising trend moved from
59% to 63% thereof.
Given the status of diarrhea in Group 1, it was indicated
that the downward trend moved from 50% to 40% at the end
of the second month. Regarding Group 2, it was observed
that the rising trend moved from 36% at the beginning of the
1rst week to 63% at the end of the eighth week.
+ere was a serious downward trend in terms of myalgia
in Group 1. Actually, the aforementioned trend moved from
63% at baseline to 9% at the end of eighth week, and this
serious trend took a quicker step at the start of the second
month. Regarding the control group, it was observed that the
changing and rising trendmoved from 40% at the baseline to
68% at the end of the second month.
+e results indicated that the status of temptation in
Group 1 was faced with a downward trend and moved from
59% to 50% throughout the research participants. +en,
a fairly stable trend was seen from the third to the sixth week.
Conversely, there was not a systematic downward trend in
the control group.
4. Discussion and Conclusion
Having conducted a two-month investigation on the re-
search participants, it was revealed that addiction with-
drawal symptoms in patients undergoing the sa0ron-based
maintenance treatment were alleviated. +e lifetime prev-
alence of drug abuse was about 20 percent [18]. Regarding
this fact that drug abuse was considered as one of the most
important problems in the realm of public health, the au-
thorities responsible for developing and promoting health in
the society were recommended to adopt solutions to combat
this challenge and its associated problems. To do this end,
this study aimed to investigate the impact of sa0ron on
symptoms of withdrawal syndrome in patients undergoing
maintenance treatment for opioid addiction. +en, 100
participants willingly participated in the study.
+eir age range was between 21 and 67 years, and the
majority of participants were young. Tavakoli et al. con-
ducted a study on higher percentage of middle-aged par-
ticipants. However, the reason for the di0erence in
results stemmed from two di0erent statistical populations.
Given a study conducted in Hamedan, it was observed that
the average age was about 30 years, which was consistent
with the results of the current study. It seems that the
addiction dilemma can encompass the majority of age
groups and, thus, this latter issue deserves due attention.
All participants in this study were male patients, which
correspond with the results of a study conducted by Hojjati
et al. It seems that addiction is more prevalent in men than
women [12].
Methadone may be considered among e0ective drug
treatment methods in connection to addiction treatment. Since
methadone is e0ective in eliminating withdrawal symptoms of
drug discontinuation for 24 hours or more, it may be argued
that methadone is useful for the treatment of addiction [13].
Methadone is one of the most e0ective opioid analgesics
that a0ect the central nervous system, and it generates such
e0ects as analgesia, euphoria, and tranquility [18].
In this study, 1ve major symptoms of withdrawal, di-
arrhea, rhinorrhea, myalgia, temptation, and loss of appetite,
were investigated.
Regarding the research results and having compared the
forenamed results with other similar studies, it was con-
cluded that sa0ron-based treatment was e0ective in allevi-
ating the symptoms of withdrawal syndrome in patients
undergoing maintenance treatment for opioid addiction.
Besides, it was indicated that similar previous studies were in
line with the results of the current study.
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